This area of our work seeks to prevent infection in the human host.
MVI has outlined two priority areas of work for the next several years, with the goal of declaring at least one product development candidate—a potential second-generation vaccine. The prevention of malaria infection is the goal of MVI’s anti-infection vaccine (AIV) program.
The focus of this priority area is the development of pre-erythrocytic (liver-stage) vaccines to interrupt malaria parasite transmission (PE-VIMTs).
The AIV approach is supported by the concept that preventing malaria infection of the human host by immunization will provide direct clinical benefit to the person immunized, and if sufficiently high coverage levels are achieved, to the wider community, by reducing the transmission of the parasite to a level where it cannot be sustained. Every person completely protected against infection is one less individual capable of transmitting the parasite back to a mosquito.
MVI’s initial target for this type of vaccine is 80 percent efficacy, which would also satisfy the criteria for a second-generation vaccine laid out in the World Health Organization’s Malaria Vaccine Technology Roadmap.
- Explore our research and development strategy.
- Explore our preferred product characteristics (PPCs) for anti-infection vaccines.
- Explore our work aimed at preventing transmission.